Valeant CEO to Step Down, Ackman Added to Board

The video discusses the departure of Mike Pearson from Valeant Pharmaceuticals, highlighting his unorthodox tactics in drug pricing and distribution. It covers the ongoing investigation into the company's accounting practices, focusing on Howard Schiller's role and the board's internal conflicts. Allegations of fraud and financial inconsistencies are explored, raising concerns about the company's governance and financial stability.

What were the unorthodox tactics implemented by Mike Pearson at Valeant?

What led to the investigation into the accounting of the pharmacy subsidiary?

What was the board's response to Howard Schiller's alleged improper behavior?

How did the company's financial reporting raise questions about its reliability?

What was the significance of the $600 million typo mentioned during the earnings call?